Barbara G.  McClung net worth and biography

Barbara McClung Biography and Net Worth

Barbara serves as Chief Legal Officer and Corporate Secretary for Caribou Biosciences, where she is responsible for all legal functions, including intellectual property strategy and portfolio management, contracts, corporate transactions, board governance, and employment law. In addition, the company’s human resources function reports to Barbara. Prior to joining Caribou in 2015, she headed the legal functions at Intarcia Therapeutics, Inc. and Cygnus, Inc. Barbara began her career as a patent attorney with E. I. du Pont de Nemours and Company, and then joined Chiron Corporation where she was patent counsel for Chiron’s vaccine division. Barbara is a member of the California, Delaware, and Pennsylvania state bars, and is a registered patent attorney before the United States Patent and Trademark Office. She received a B.A. from the University of California, San Diego an M.A. from the University of Pennsylvania, and a J.D. from the University of Pennsylvania Law School.

What is Barbara G. McClung's net worth?

The estimated net worth of Barbara G. McClung is at least $521,114.85 as of February 21st, 2025. Ms. McClung owns 443,502 shares of Caribou Biosciences stock worth more than $521,115 as of February 27th. This net worth evaluation does not reflect any other investments that Ms. McClung may own. Additionally, Ms. McClung receives a salary of $669,310.00 as Insider at Caribou Biosciences. Learn More about Barbara G. McClung's net worth.

How old is Barbara G. McClung?

Ms. McClung is currently 69 years old. There are 5 older executives and no younger executives at Caribou Biosciences. Learn More on Barbara G. McClung's age.

What is Barbara G. McClung's salary?

As the Insider of Caribou Biosciences, Inc., Ms. McClung earns $669,310.00 per year. The highest earning executive at Caribou Biosciences is Dr. Rachel E. Haurwitz Ph.D., Co-Founder, CEO, President & Director, who commands a salary of $979,080.00 per year. Learn More on Barbara G. McClung's salary.

How do I contact Barbara G. McClung?

The corporate mailing address for Ms. McClung and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at investor.relations@cariboubio.com. Learn More on Barbara G. McClung's contact information.

Has Barbara G. McClung been buying or selling shares of Caribou Biosciences?

During the last quarter, Barbara G. McClung has sold $4,811.40 of Caribou Biosciences stock. Most recently, Barbara G. Mcclung sold 3,564 shares of the business's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $1.35, for a transaction totalling $4,811.40. Following the completion of the sale, the insider now directly owns 443,502 shares of the company's stock, valued at $598,727.70. Learn More on Barbara G. McClung's trading history.

Who are Caribou Biosciences' active insiders?

Caribou Biosciences' insider roster includes Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Steven Kanner (Insider), and Barbara McClung (Insider). Learn More on Caribou Biosciences' active insiders.

Are insiders buying or selling shares of Caribou Biosciences?

During the last year, Caribou Biosciences insiders bought shares 1 times. They purchased a total of 17,360 shares worth more than $24,651.20. During the last year, insiders at the sold shares 1 times. They sold a total of 3,564 shares worth more than $4,811.40. The most recent insider tranaction occured on February, 21st when insider Barbara G Mcclung sold 3,564 shares worth more than $4,811.40. Insiders at Caribou Biosciences own 9.5% of the company. Learn More about insider trades at Caribou Biosciences.

Information on this page was last updated on 2/21/2025.

Barbara G. McClung Insider Trading History at Caribou Biosciences

See Full Table

Barbara G. McClung Buying and Selling Activity at Caribou Biosciences

This chart shows Barbara G Mcclung's buying and selling at Caribou Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$4.81ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4k-$2k$0$2k$4kTotal Insider BuyingTotal Insider Selling

Caribou Biosciences Company Overview

Caribou Biosciences logo
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Read More

Today's Range

Now: $1.18
Low: $1.16
High: $1.24

50 Day Range

MA: $1.51
Low: $1.20
High: $1.88

2 Week Range

Now: $1.18
Low: $1.16
High: $8.33

Volume

374,591 shs

Average Volume

1,354,989 shs

Market Capitalization

$106.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.31